US grants first-of-a-kind approval for Aprecia’s epilepsy tablets exploiting porous structure

Aprecia pharmaceuticals

The large, porous tablets rapidly disintegrate in contact with water, and can package controlled, personalised dosages

The first ever approval by the US Food and Drug Administration (FDA) of a 3D printed tablet promises to make medications easier to swallow than existing formulations. US firm Aprecia uses an aqueous fluid to stitch together multiple layers of powder in its Spritam pill, a reformulation of anti-epileptic seizure drug levetiracetam. Unlike conventional compressed tablets, this gives the drug a porous structure that quickly disintegrates in liquid. This is particularly useful for patients who otherwise struggle to take medication, such as children, who comprise around a sixth of the nearly three million US epileptics. Spritam is ‘first in a line of central nervous system products’ that Aprecia will submit to the FDA ‘over the next several years’ says chief executive Don Wetherhold.

Aprecia’s ZipDose 3D printing technology builds on a concept developed by Michael Cima and colleagues at Massachusetts Institute of Technology (MIT), whose patents Aprecia has exclusively licensed for pharmaceutical applications. Cima started his work in this area in 1990, so this approval has been a long time coming, but now it’s here he says he’s ‘ecstatic’. ‘Arguably these dosage forms produced by Aprecia will soon be the largest volume mass-manufactured object made from these techniques,’ he enthuses.

Wetherhold emphasises that Aprecia has added its own proprietary knowledge to the MIT technology. ‘We have invested considerable time, talent and resources to achieve manufacturing scale,’ he says. The firm’s ‘binder jetting’ approach uses two inputs, one powder, one liquid. ‘Our process spreads thin layers of powder and selectively deposits liquid droplets to bind the powder together, layer-by-layer, to make three dimensional parts,’ he explains.